MX2023011267A - Anticuerpo triespecífico dirigido a cd79b, cd20, y cd3. - Google Patents

Anticuerpo triespecífico dirigido a cd79b, cd20, y cd3.

Info

Publication number
MX2023011267A
MX2023011267A MX2023011267A MX2023011267A MX2023011267A MX 2023011267 A MX2023011267 A MX 2023011267A MX 2023011267 A MX2023011267 A MX 2023011267A MX 2023011267 A MX2023011267 A MX 2023011267A MX 2023011267 A MX2023011267 A MX 2023011267A
Authority
MX
Mexico
Prior art keywords
binding fragments
antigen
antibodies
cd79b
multispecific
Prior art date
Application number
MX2023011267A
Other languages
English (en)
Inventor
Sanjaya Singh
Rajkumar Ganesan
Danlin Yang
Ulrike Philippar
Anna Kuchnio
Cassandra L Lowenstein
Nele Vloemans
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of MX2023011267A publication Critical patent/MX2023011267A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

En la presente descripción se proporcionan anticuerpos multiespecíficos, que incluyen anticuerpos triespecíficos que se unen a CD79b, CD20 y CD3, y anticuerpos biespecíficos que se unen a CD79b y CD3, y fragmentos de unión al antígeno multiespecíficos de estos; además, se describen polinucleótidos relacionados que tienen la capacidad de codificar anticuerpos multiespecíficos o fragmentos de unión al antígeno multiespecíficos proporcionados, células que expresan anticuerpos multiespecíficos o fragmentos de unión al antígeno multiespecíficos proporcionados, así como vectores asociados y anticuerpos multiespecíficos o fragmentos de unión al antígeno multiespecíficos marcados de forma detectable; adicionalmente, se describen métodos para producir y usar los anticuerpos multiespecíficos y los fragmentos de unión al antígeno multiespecíficos proporcionados; en la presente descripción se proporcionan además anticuerpos aislados que se unen a CD79b y fragmentos de unión al antígeno de estos; además, se describen polinucleótidos relacionados que tienen la capacidad de codificar anticuerpos específicos para CD79b o fragmentos de unión al antígeno proporcionados, células que expresan los anticuerpos específicos para CD79b o fragmentos de unión al antígeno proporcionados, así como vectores asociados y anticuerpos específicos para CD79b o fragmentos de unión al antígeno etiquetados de forma detectable; adicionalmente, se describen métodos para producir y usar los anticuerpos específicos para CD79b y los fragmentos de unión al antígeno proporcionados.
MX2023011267A 2021-03-24 2022-03-23 Anticuerpo triespecífico dirigido a cd79b, cd20, y cd3. MX2023011267A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163165501P 2021-03-24 2021-03-24
US202163286309P 2021-12-06 2021-12-06
PCT/EP2022/057654 WO2022200443A1 (en) 2021-03-24 2022-03-23 TRISPECIFIC ANTIBODY TARGETING CD79b, CD20, AND CD3

Publications (1)

Publication Number Publication Date
MX2023011267A true MX2023011267A (es) 2023-12-14

Family

ID=81388798

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023011267A MX2023011267A (es) 2021-03-24 2022-03-23 Anticuerpo triespecífico dirigido a cd79b, cd20, y cd3.

Country Status (15)

Country Link
US (1) US20220315663A1 (es)
EP (1) EP4314070A1 (es)
JP (1) JP2024511115A (es)
KR (1) KR20230160874A (es)
AU (1) AU2022244114A1 (es)
BR (1) BR112023019484A2 (es)
CA (1) CA3214594A1 (es)
CL (1) CL2023002837A1 (es)
CO (1) CO2023013511A2 (es)
DO (1) DOP2023000204A (es)
IL (1) IL306108A (es)
MX (1) MX2023011267A (es)
TW (1) TW202304988A (es)
UY (1) UY39685A (es)
WO (1) WO2022200443A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL306132A (en) * 2021-03-24 2023-11-01 Janssen Biotech Inc Proteins containing CD3 antigen binding sites and uses thereof
WO2024097797A1 (en) * 2022-11-02 2024-05-10 Medisix Therapeutics, Inc. Blockade of cd3 expression and chimeric antigen receptors for immunotherapy

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US20020142000A1 (en) 1999-01-15 2002-10-03 Digan Mary Ellen Anti-CD3 immunotoxins and therapeutic uses therefor
AU2005282700A1 (en) 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
TWI671403B (zh) 2005-03-31 2019-09-11 中外製藥股份有限公司 控制組裝之多肽的製造方法
DE102005028778A1 (de) 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
US8236308B2 (en) 2005-10-11 2012-08-07 Micromet Ag Composition comprising cross-species-specific antibodies and uses thereof
EP1973576B1 (en) 2005-11-28 2019-05-15 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
WO2007147901A1 (en) 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
GB0624500D0 (en) * 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
MX2009010611A (es) 2007-04-03 2010-03-26 Micromet Ag Enlazadores biespecificos, especificos para especies.
CN101687915B8 (zh) 2007-04-03 2018-08-03 安进研发（慕尼黑）股份有限公司 跨物种特异性CD3-ε结合结构域
BRPI0809594A2 (pt) 2007-04-03 2019-08-27 Micromet Ag polipeptídeo, seqüência de ácido nucléico, vetor, hospedeiro, processo para a produção de um polipeptídeo, composição farmacêutica, uso de um polipeptídeo, método para prevenção, tratamento ou melhora de uma doença, em um indivíduo com necessidade do mesmo, kit, método para a identificação de um polipeptídeo(s)
BRPI0919841A2 (pt) 2008-10-01 2014-11-18 Micromet Ag Anticorpo de cadeia unica biespecifico de psmaxcd3, especifico de especies cruzadas
DK2352763T4 (da) 2008-10-01 2022-10-17 Amgen Res Munich Gmbh Bispecifikke enkeltkædede antistoffer med specificitet for højmolekylære målantigener
EP2352765B1 (en) 2008-10-01 2018-01-03 Amgen Research (Munich) GmbH Cross-species-specific single domain bispecific single chain antibody
RS55218B1 (sr) 2008-10-31 2017-02-28 Janssen Biotech Inc Kompozicije fibronektin tip iii skalno baziranih domena, metode i upotrebe
JP5873335B2 (ja) 2009-02-12 2016-03-01 ヤンセン バイオテツク，インコーポレーテツド フィブロネクチンｉｉｉ型ドメインに基づくスカフォールド組成物、方法及び使用
EP2424567B1 (en) 2009-04-27 2018-11-21 OncoMed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
LT3248462T (lt) 2010-03-31 2024-05-27 Ablexis, Llc Pelių genų inžinerija, skirta chimerinių antikūnų gamybai
MX353144B (es) 2010-04-20 2017-12-20 Genmab As Proteinas que contienen fc de anticuerpos heterodimericos y metodos para produccion de las mismas.
CN103429620B (zh) 2010-11-05 2018-03-06 酵活有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
PT2773671T (pt) 2011-11-04 2021-12-14 Zymeworks Inc Geração de anticorpo heterodimérico estável com mutações no domínio fc
US9493563B2 (en) * 2013-11-04 2016-11-15 Glenmark Pharmaceuticals S.A. Production of T cell retargeting hetero-dimeric immunoglobulins
CA2874083C (en) * 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
EP3227336B1 (en) * 2014-12-05 2019-07-03 F.Hoffmann-La Roche Ag Anti-cd79b antibodies and methods of use
GB201601077D0 (en) * 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibody molecule
HUE050556T2 (hu) 2015-08-17 2020-12-28 Janssen Pharmaceutica Nv Anti-BCMA ellenanyagok, BCMA-t és CD3-at kötõ bispecifikus antigénkötõ molekulák és ezek alkalmazásai
TWI781108B (zh) 2016-07-20 2022-10-21 比利時商健生藥品公司 抗ｇｐｒｃ５ｄ抗體、結合ｇｐｒｃ５ｄ與ｃｄ３之雙特異性抗原結合分子及其用途
WO2019060695A1 (en) 2017-09-22 2019-03-28 Kite Pharma, Inc. CHIMERIC POLYPEPTIDES AND USES THEREOF
JOP20190116A1 (ar) 2018-05-24 2019-11-24 Janssen Biotech Inc الأجسام المضادة لتكتل التمايز 33 (cd33)، والأجسام المضادة ثنائية النوعية لتكتل التمايز 33 (cd33)/تكتل التمايز 3 (cd3) واستخداماتها
EP4004057A1 (en) * 2019-07-26 2022-06-01 Janssen Biotech, Inc. Proteins comprising kallikrein related peptidase 2 antigen binding domains and their uses

Also Published As

Publication number Publication date
US20220315663A1 (en) 2022-10-06
AU2022244114A9 (en) 2023-11-16
KR20230160874A (ko) 2023-11-24
EP4314070A1 (en) 2024-02-07
CA3214594A1 (en) 2022-09-29
DOP2023000204A (es) 2024-04-30
CL2023002837A1 (es) 2024-02-02
WO2022200443A1 (en) 2022-09-29
CO2023013511A2 (es) 2023-10-19
UY39685A (es) 2022-09-30
AU2022244114A1 (en) 2023-11-09
JP2024511115A (ja) 2024-03-12
IL306108A (en) 2023-11-01
TW202304988A (zh) 2023-02-01
BR112023019484A2 (pt) 2023-12-05

Similar Documents

Publication Publication Date Title
CR20230398A (es) Anticuerpo triespecífico dirigido a bcma, gprc5d, y cd3
MX2023011267A (es) Anticuerpo triespecífico dirigido a cd79b, cd20, y cd3.
PH12019500550A1 (en) Bi specific anti-muc16-cd3 antibodies and anti-muc16 drug conjugates
PH12017501732A1 (en) Therapeutic antibodies and their uses
MY194642A (en) Antibodies binding to cd3
PH12019500603A1 (en) Anti-steap2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind steap2 and cd3, and uses thereof
CR20220019A (es) Anticuerpos que se fijan a gprc5d
PH12021550031A1 (en) BISPECIFIC ANTI-BCMA x ANTI-CD3 ANTIBODIES AND USES THEREOF
MX2017015380A (es) Metodos para utilizar proteinas de enlace biespecificas cd3 y cd33.
SG10201900015XA (en) Bispecific cd33 and cd3 binding proteins
MX2022003110A (es) Anticuerpos biespecificos contra ceacam5 y cd3.
MX336869B (es) Anticuerpos que bloquean espicificamente la actividad biologica de un antigeno de tumor.
WO2021207242A3 (en) Anti-mesothelin antigen-binding molecules and uses thereof
CR20220628A (es) Anticuerpos que se unen a cd3
MX2021014973A (es) Anticuerpos anti-cd3 de alta afinidad y metodos para su generacion y uso.
CR20220637A (es) Anticuerpos que se unen a cd3 y cd19
MX2023009615A (es) Moleculas de union anti-cd123 y usos de estas.
MX2023008909A (es) Proteínas de unión a psma y usos de estas.
MX2022006714A (es) Métodos de tratamiento del mieloma múltiple con anticuerpos anti-bcma x anti-cd3 bisespecíficos.
WO2022159653A3 (en) Bispecific chimeric antigen receptors binding to cd19 and cd22
CR20200391A (es) Moléculas biespecíficas de unión al antígeno y métodos de uso
MX2022003833A (es) Anticuerpos anti-kir3dl3 y sus usos.
MX2022009815A (es) Moleculas de union biespecificas.
MX2023011712A (es) Anticuerpos anti receptor de adhesion acoplado a proteinas g e2 (adgre2) y usos de los mismos.
MX2022002363A (es) Sistema receptor de antígeno quimérico y usos de este.